Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease
February 21, 2018 18:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product...
Mesoblast to Present at 36th Annual J.P. Morgan Healthcare Conference
January 11, 2018 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will present a corporate update at the 36th annual J.P. Morgan Healthcare Conference...
Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices
December 21, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted...
Mesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes Enrollment
December 20, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its proprietary allogeneic mesenchymal stem...
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
December 14, 2017 19:34 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia and LEUVEN, Belgium, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) and TiGenix NV (Euronext Brussels:TIG) (Nasdaq:TIG) today announce...
Mesoblast Named Global Technology Leader in Cell Therapy Industry
December 07, 2017 17:33 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell...
Chairman’s Address to the Mesoblast 2017 Annual General Meeting
November 16, 2017 06:00 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Welcome to the Mesoblast 2017 Annual General Meeting. It has been a significant year for Mesoblast. Our proprietary and...
Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017
November 14, 2017 17:35 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with an update on its corporate strategy, operational...
Mesoblast to Host First Quarter Financial Results Webcast and Conference Call
November 13, 2017 16:30 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced it will report financial results for the first quarter ended September...
Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients
November 10, 2017 09:49 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that results from the randomized, placebo-controlled Phase 2 trial of...